Kate Oliver

435 total citations
27 papers, 305 citations indexed

About

Kate Oliver is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kate Oliver has authored 27 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Kate Oliver's work include Endometrial and Cervical Cancer Treatments (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Treatment and Pharmacology (4 papers). Kate Oliver is often cited by papers focused on Endometrial and Cervical Cancer Treatments (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Treatment and Pharmacology (4 papers). Kate Oliver collaborates with scholars based in United States, Australia and Switzerland. Kate Oliver's co-authors include John Farley, Caela Miller, G. Larry Maxwell, Thomas P. Conrads, Chad A. Hamilton, Lindsey Enewold, G. Scott Rose, Kangmin Zhu, David Mitchell and Pang-ning Teng and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Kate Oliver

25 papers receiving 301 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kate Oliver United States 8 119 109 89 76 47 27 305
Tayyebeh M. Nazeran Canada 10 149 1.3× 267 2.4× 45 0.5× 164 2.2× 54 1.1× 13 433
Jitka Hausnerová Czechia 10 142 1.2× 84 0.8× 70 0.8× 63 0.8× 14 0.3× 37 297
G. C. Torre Italy 5 104 0.9× 153 1.4× 69 0.8× 56 0.7× 24 0.5× 8 325
Liudmila Velikokhatnaya United States 6 113 0.9× 166 1.5× 95 1.1× 83 1.1× 12 0.3× 7 359
Amy Guppy United Kingdom 6 80 0.7× 112 1.0× 105 1.2× 26 0.3× 63 1.3× 10 298
J. Lahodny Austria 7 76 0.6× 102 0.9× 116 1.3× 41 0.5× 28 0.6× 13 366
E. Vaucel France 6 139 1.2× 218 2.0× 64 0.7× 104 1.4× 17 0.4× 12 421
Daniel Boehm Germany 11 149 1.3× 51 0.5× 197 2.2× 53 0.7× 27 0.6× 25 540
Shannon MacLaughlan United States 9 177 1.5× 156 1.4× 88 1.0× 34 0.4× 26 0.6× 15 397
C. Mendiola Spain 11 86 0.7× 93 0.9× 185 2.1× 69 0.9× 24 0.5× 28 388

Countries citing papers authored by Kate Oliver

Since Specialization
Citations

This map shows the geographic impact of Kate Oliver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate Oliver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate Oliver more than expected).

Fields of papers citing papers by Kate Oliver

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate Oliver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate Oliver. The network helps show where Kate Oliver may publish in the future.

Co-authorship network of co-authors of Kate Oliver

This figure shows the co-authorship network connecting the top 25 collaborators of Kate Oliver. A scholar is included among the top collaborators of Kate Oliver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate Oliver. Kate Oliver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bruce, Justine Y., Randall J. Kimple, Menggang Yu, et al.. (2024). Safety and Toxicity of Iopofosine I-131 with External Beam Radiation Therapy (EBRT) in Recurrent or Metastatic Head and Neck Cancer (HNC): Results of a Phase 1 Study. International Journal of Radiation Oncology*Biology*Physics. 118(5). e36–e37. 1 indexed citations
2.
3.
Ailawadhi, Sikander, Patrick J. Stiff, Emad Ibrahim, et al.. (2021). CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial. Blood. 138(Supplement 1). 1652–1652. 7 indexed citations
4.
Puccetti, Diane, Mario Otto, Daniel A. Morgenstern, et al.. (2020). EPCT-09. CLR 131 IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC MALIGNANCIES. Neuro-Oncology. 22(Supplement_3). iii305–iii305. 1 indexed citations
5.
Oliver, Kate, et al.. (2019). Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 134(Supplement_1). 1864–1864. 4 indexed citations
6.
Tian, Chunqiao, Kate Oliver, Nicholas W. Bateman, et al.. (2019). Factors to explain racial disparity in survival for women with uterine cancer: Further investigations by histologic subtype. Gynecologic Oncology. 154. 23–24.
7.
Ailawadhi, Sikander, Patrick J. Stiff, Emad Ibrahim, et al.. (2019). Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 134(Supplement_1). 144–144. 4 indexed citations
8.
9.
Teng, Pang-ning, Nicholas W. Bateman, Guisong Wang, et al.. (2017). Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. Human Cell. 30(3). 226–236. 7 indexed citations
10.
Grant, Robert A., et al.. (2015). OP01THE UK TOP 10 CLINICAL RESEARCH PRIORITIES IN NEURO-ONCOLOGY. Neuro-Oncology. 17(suppl 8). viii16.1–viii16. 5 indexed citations
11.
Miller, Caela, Kate Oliver, & John Farley. (2014). MEK1/2 inhibitors in the treatment of gynecologic malignancies. Gynecologic Oncology. 133(1). 128–137. 91 indexed citations
12.
Lowery, William J., Michael P. Stany, Neil T. Phippen, et al.. (2014). Survival advantage of marriage in uterine cancer patients contrasts poor outcome for widows: A Surveillance, Epidemiology and End Results study. Gynecologic Oncology. 136(2). 328–335. 18 indexed citations
13.
Teng, Pang-ning, Nicholas W. Bateman, Kate Oliver, et al.. (2014). Enhanced gynecologic cancer cell killing through pharmacologic inhibition of the ataxia telangiectasia and Rad3-related kinase. Gynecologic Oncology. 133. 108–109. 1 indexed citations
14.
Oliver, Kate, et al.. (2012). Spontaneous Resolution of Mirror Syndrome following Demise of Hydropic Twin. Case Reports in Obstetrics and Gynecology. 2012. 1–3. 3 indexed citations
15.
Oliver, Kate, et al.. (2012). Innovation in Hospital Quality Improvement Activities—Acute Postoperative Pain Management (APOP) Self-Help Toolkit Audits as an Example. Journal for Healthcare Quality. 34(4). 45–59. 5 indexed citations
16.
Oliver, Kate, Lindsey Enewold, Kangmin Zhu, et al.. (2011). Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment. Gynecologic Oncology. 123(1). 76–81. 36 indexed citations
17.
Oliver, Kate & John Farley. (2010). Cisplatin plus Cetuximab in the Treatment of Recurrent and Persistent Cancers of the Cervix. 6. 45–45. 1 indexed citations
18.
Mulkerin, Daniel, Noelle K. LoConte, Kyle D. Holen, et al.. (2009). A phase I study of an oral simulated FOLFOX with high dose capecitabine. Investigational New Drugs. 27(5). 461–468. 6 indexed citations
19.
Schelman, William R., Howard H. Bailey, Kyle D. Holen, et al.. (2008). A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 62(4). 727–733. 7 indexed citations
20.
Oliver, Kate. (2004). O'Connor's Good Country People. The Explicator. 62(4). 233–236.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tayyebeh M. Nazeran Breakdown of academic impact, for papers by Jitka Hausnerová Breakdown of academic impact, for papers by G. C. Torre Breakdown of academic impact, for papers by Liudmila Velikokhatnaya Breakdown of academic impact, for papers by Amy Guppy Breakdown of academic impact, for papers by J. Lahodny Breakdown of academic impact, for papers by E. Vaucel Breakdown of academic impact, for papers by Daniel Boehm Breakdown of academic impact, for papers by Shannon MacLaughlan Breakdown of academic impact, for papers by C. Mendiola
Rankless by CCL
2026